US Patent

US7959945 — Dispersible bosentan tablet

Formulation · Assigned to Actelion Pharmaceuticals Ltd · Expires 2027-12-28 · 2y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a dispersible tablet formulation of the compound bosentan.

USPTO Abstract

The invention relates to dispersible tablets comprising the compound 4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(pyrimidin-2-yl)-pyrimidin-4-yl]-benzenesulfonamide.

Drugs covered by this patent

Patent Metadata

Patent number
US7959945
Jurisdiction
US
Classification
Formulation
Expires
2027-12-28
Drug substance claim
No
Drug product claim
Yes
Assignee
Actelion Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.